A biomarker is needed to evaluate therapies for primary progressive MS (PPMS).
We used novel MRI providing both general atrophy and specific myelin measures.
We studied brain and cervical spinal cord in PPMS and healthy controls.
Brain and spinal cord volume and myelin measures were reduced in PPMS vs controls.
MRI measures described cognitive, fine motor and ambulatory disability scores.